Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 132 Pancreatic Neoplasms 36 Esophageal Neoplasms 19 Biliary Tract Neoplasms 18 Colorectal Neoplasms 17 Esophageal Squamous Cell Carcinoma 12 Neoplasm Metastasis 10 Cholangiocarcinoma 7 Carcinoma, Non-Small-Cell Lung 7 Gastrointestinal Neoplasms 6 Nasopharyngeal Carcinoma 5 Colonic Neoplasms 5 Adenocarcinoma 5 Neoplasms 4 Head and Neck Neoplasms 4 Advanced Pancreatic Cancer 4 Advanced Gastric Cancer 4 Recurrence 3 Rectal Neoplasms 3 Gastric Adenocarcinoma 3 Advanced Solid Tumors 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 NSCLC 2 Locally Advanced Pancreatic Cancer 2 Locally Advanced Gastric Cancer 2 Gastric Cancer Peritoneal Metastases 2 Gallbladder Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pan-tumor × S 1 (combination) × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡